ID   HCC4011/R
AC   CVCL_S747
SY   HCC4011/ER; HCC4011R
DR   cancercelllines; CVCL_S747
DR   Cosmic; 1890458
DR   Wikidata; Q54881734
RX   PubMed=22773810;
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (from parent cell line).
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_S700 ! HCC4011
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 11
//
RX   PubMed=22773810; DOI=10.1073/pnas.1203530109;
RA   Ohashi K., Sequist L.V., Arcila M.E., Moran T., Chmielecki J.,
RA   Lin Y.-L., Pan Y.-M., Wang L., de Stanchina E., Shien K., Aoe K.,
RA   Toyooka S., Kiura K., Fernandez-Cuesta L., Fidias P., Yang J.C.-H.,
RA   Miller V.A., Riely G.J., Kris M.G., Engelman J.A., Vnencak-Jones C.L.,
RA   Dias-Santagata D., Ladanyi M., Pao W.;
RT   "Lung cancers with acquired resistance to EGFR inhibitors occasionally
RT   harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or
RT   MEK1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:E2127-E2133(2012).
//